Stem cell and regenerative medicine therapies hold tremendous promise. They can repair damaged tissues, treat serious diseases, and transform patient care.
That promise also comes with responsibility.
Patients deserve treatments that are safe, effective, and supported by scientific evidence. That is why CIRM has long advocated for clear standards governing the development and delivery of regenerative medicine therapies.
Setting Standards for Safe Regenerative Medicine
In 2020, CIRM published a framework outlining key benchmarks for the responsible delivery of stem cell and regenerative medicine products.
At its core, the framework calls for therapies to be delivered in settings where:
- The FDA authorizes the product.
- An Institutional Review Board (IRB) or ethics board provides oversight.
- Qualified healthcare professionals administer treatment.
- Specialized clinical centers deliver care.
- Providers monitor patients and track outcomes over time.
These standards help protect patients while supporting the responsible advancement of regenerative medicine.
Why FDA Oversight Matters
In April 2021, Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research, reaffirmed the agency’s commitment to regulating regenerative medicine products.
The FDA requires developers of new cell and gene therapies to obtain an Investigational New Drug (IND) authorization before testing products in humans.
IND authorization serves several important purposes.
It allows regulators to evaluate how developers manufacture a product. It also requires evidence supporting the therapy’s scientific rationale and potential benefit for a specific disease.
Dr. Marks emphasized that products marketed without appropriate authorization can place patients at risk.
He also noted that the FDA is prepared to take enforcement action against clinics and companies that fail to comply with federal regulations.
At CIRM, every funded clinical trial and every study conducted through the Alpha Stem Cell Clinics Network must operate under an active IND authorization.
Why Living Medicines Require Special Care
Many regenerative medicine treatments use living cells or tissues.
Because these therapies contain active biological components, they behave differently from traditional drugs.
Their ability to repair, replace, or restore damaged tissues gives them enormous therapeutic potential.
However, that same complexity requires careful oversight.
Researchers must fully understand how these therapies are manufactured, stored, delivered, and monitored.
Without proper regulation, patients cannot know whether a product contains the intended cells, meets quality standards, or has undergone appropriate safety testing.
The Risks of Unproven Treatments
Unregulated stem cell products create significant risks.
Some clinics market treatments without sufficient evidence that they are safe or effective. Others offer therapies that have not undergone rigorous clinical testing.
In these situations, patients may receive products with unknown ingredients, inconsistent quality, or inadequate safety data.
The consequences can be serious.
Several patients have experienced severe complications from unapproved stem cell interventions. One widely reported case involved three women who lost vision after receiving unauthorized stem cell injections for eye disease.
These cases highlight why regulatory review and scientific validation matter.
Patients deserve therapies supported by evidence, not marketing claims.
Building Trust Through Evidence
FDA authorization requires developers to provide detailed scientific and clinical data before moving forward.
Researchers must demonstrate that a therapy:
- Meets quality standards.
- Has an acceptable safety profile.
- Shows potential to benefit patients.
- Targets a specific disease or condition.
This process protects patients and strengthens confidence in the field.
While clinical testing takes time, rigorous evaluation helps ensure that promising therapies advance responsibly.
Advancing Regenerative Medicine the Right Way
CIRM supports the development of transformative therapies, but we also believe innovation must be accompanied by accountability.
Patients facing serious diseases often have limited treatment options. That reality can make them especially vulnerable to exaggerated claims and unproven interventions.
Strong oversight helps protect patients while allowing legitimate therapies to move forward.
The FDA’s commitment to enforcing regulatory standards supports that goal.
Regenerative medicine has the potential to change countless lives. Realizing that potential requires treatments that are regulated, reliable, and reputable.
By insisting on scientific rigor, transparency, and patient safety, the field can continue advancing therapies that deliver meaningful benefits while minimizing unnecessary risks.
